The CyberKnife® Robotic Radiosurgery System was cleared by the U.S. Food and Drug Administration in 2001 to treat tumors anywhere in the body, including the prostate. Despite its name, the CyberKnife System is not a surgical procedure. In fact, there is no cutting involved. Instead, the CyberKnife System delivers high doses of radiation directly to the prostate cancer. The CyberKnife System offers patients a minimally invasive, alternative prostate cancer treatment. Prostate cancer treatments with the CyberKnife System are typically performed on an outpatient basis over a period of two weeks, requiring no overnight hospital stays. Most patients experience minimal to no side effects with a quick recovery time. With conventional radiotherapy, treatment can last up to eight weeks.